Logo

GOSS

Gossamer Bio, Inc.

GOSS

Gossamer Bio, Inc. • NASDAQ
$3.34 ▲ 0.00% (+0.00)
Market Cap $758.40 M
52w High $3.60
52w Low $0.67
Dividend Yield 0%
P/E -4.84
Volume 854.78K
Outstanding Shares 227.07M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.294M ▲ $62.408M ▲ $-48.221M ▼ -362.728% ▼ $-0.21 ▼ $-45.467M ▼
Q2-2025 $11.489M ▲ $50.254M ▲ $-38.273M ▼ -333.127% ▲ $-0.17 ▼ $-35.316M ▼
Q1-2025 $9.889M ▲ $46.699M ▲ $-36.638M ▼ -370.492% ▼ $-0.16 ▼ $-33.55M ▼
Q4-2024 $9.379M ▼ $45.507M ▲ $-33.029M ▼ -352.159% ▼ $-0.15 ▼ $-31.626M ▼
Q3-2024 $9.48M $43.399M $-30.803M -324.926% $-0.14 $-28.103M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $180.224M ▼ $208.82M ▼ $291.153M ▲ $-82.333M ▼
Q2-2025 $212.918M ▼ $240.925M ▼ $287.032M ▲ $-46.107M ▼
Q1-2025 $257.934M ▼ $280.589M ▼ $286.839M ▲ $-6.25M ▼
Q4-2024 $294.518M ▼ $315.292M ▼ $285.8M ▼ $29.492M ▼
Q3-2024 $327.034M $350.879M $296.743M $54.136M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-48.221M ▼ $-36.167M ▲ $17.014M ▼ $1.872M ▲ $-17.376M ▼ $-36.167M ▲
Q2-2025 $-38.273M ▼ $-47.061M ▼ $44.126M ▲ $94K ▼ $-2.712M ▲ $-47.114M ▼
Q1-2025 $-36.638M ▼ $-39.724M ▼ $22.062M ▼ $504K ▲ $-17.053M ▼ $-39.75M ▼
Q4-2024 $-33.029M ▼ $-35.481M ▼ $53.216M ▲ $0 ▼ $17.61M ▲ $-35.481M ▼
Q3-2024 $-30.803M $-32.033M $-26.754M $281K $-58.413M $0

Revenue by Products

Product Q2-2024Q3-2024Q2-2025Q3-2025
License and Service
License and Service
 $90.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Gossamer is still essentially a pre‑revenue biotech. Product sales are almost nonexistent, and the company has been running at a steady loss for years as it funds late‑stage trials. The good news is that losses have clearly narrowed recently, suggesting tighter cost control and likely help from partnership income. The bad news is that the business model is still “spend on R&D now, hope for future drug sales later.” Profitability depends almost entirely on whether seralutinib eventually reaches the market and gains traction. In short, the income statement shows a typical late‑stage biotech pattern: large ongoing expenses, tiny revenue, and improving but still significant net losses per share.

Balance Sheet

Balance Sheet The balance sheet is lean and highly geared toward funding one main program. Total assets are modest, with cash making up a meaningful but not dominant share. Cash levels are well below where they were a few years ago, although they ticked up most recently, likely reflecting partnership payments or financing. Debt is sizeable relative to the overall asset base and especially large compared with the small equity cushion. Equity only recently turned positive after being negative, which means the company does not have a deep buffer if things go wrong. Overall, the balance sheet looks typical for a small, late‑stage biotech: workable for the near term if plans stay on track, but not especially robust if trials disappoint or timelines slip.

Cash Flow

Cash Flow Cash flow follows the classic “cash‑burn” pattern of a clinical‑stage biotech. For several years, the company used a substantial amount of cash in its operations to fund R&D and overhead. Capital spending on equipment and facilities has been very small, so free cash flow has tracked closely with operating cash burn. Most recently, operating cash flow has improved sharply and is close to breakeven. That likely reflects external funding, milestone payments, and spending cuts rather than a shift to a self‑funding business model. Taken together, the cash flow statement shows that Gossamer still depends heavily on outside capital and partnerships. According to company commentary, the current cash runway is expected to last into 2027, but long‑term sustainability still hinges on successful approval and commercialization of seralutinib.

Competitive Edge

Competitive Edge Gossamer’s competitive position is narrow but focused. The company is concentrating on pulmonary hypertension, with seralutinib as a potential first‑in‑class inhaled tyrosine kinase inhibitor. Its main points of differentiation are: - Targeted delivery to the lungs via an inhaler, aiming for strong local effect with fewer whole‑body side effects. - A mechanism that tries to address underlying disease processes, not just symptoms. A major plus is the global collaboration with Chiesi, which brings commercial, regulatory, and geographic reach that Gossamer could not easily build on its own. However, the competitive landscape is intense. Large companies like Merck are already active with disease‑modifying therapies, and existing treatments are well established. Gossamer’s entire competitive story hinges on seralutinib proving clearly beneficial and safe, and on carving out a role either as an alternative or as a combination partner to existing drugs. The focus creates clarity but also concentration risk: one main drug, in one core disease area, against much larger competitors.

Innovation and R&D

Innovation and R&D Innovation is the company’s main strength. Seralutinib is an inhaled small‑molecule drug that blocks several key signaling pathways involved in the blood vessel changes seen in pulmonary hypertension. By targeting the lungs directly, it aims to change the course of the disease rather than just widen blood vessels. Gossamer is running late‑stage trials in two indications: pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Key Phase 3 data for the first indication are expected in 2026, with the second program following behind. The company has deliberately shut down other programs to focus resources on seralutinib. It is also exploring an option to acquire Respira Therapeutics’ inhaled therapy RT234, which could broaden the portfolio but is still at an earlier strategic stage. The R&D approach is high conviction and high risk: strong scientific rationale and differentiated delivery, but a heavy reliance on one lead asset delivering positive Phase 3 results and regulatory approvals.

Summary

Gossamer Bio is a late‑stage, research‑driven biotech centered almost entirely on one drug, seralutinib, for pulmonary hypertension. Financially, the company shows the typical profile of a pre‑commercial biotech: minimal revenue, sizeable but improving losses, a thin equity base, meaningful debt, and historical cash burn that seems to have eased with recent funding and cost controls. The balance sheet and cash flows look adequate for planned trials in the near to medium term but leave limited margin for major setbacks without new capital or additional deals. Strategically, the story is about focused innovation. Seralutinib’s inhaled, potentially disease‑modifying profile, plus the partnership with Chiesi, give Gossamer a credible shot at carving out a space in a competitive and clinically important market. At the same time, competition from large players, the binary nature of Phase 3 outcomes, regulatory uncertainty, and high dependence on a single asset all represent significant risks. The company’s future value and financial profile will be largely determined by whether seralutinib’s late‑stage trials confirm its promise and how well Gossamer and Chiesi execute on approval and commercialization if they do.

NEWS

November 24, 2025 · 4:01 PM UTC

Gossamer Bio to Participate in Upcoming Investor Conferences

Read more

November 7, 2025 · 5:30 PM UTC

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 7, 2025 · 7:31 AM UTC

Gossamer Bio to Participate in Upcoming Investor Conferences

Read more

November 5, 2025 · 4:01 PM UTC

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Read more

September 25, 2025 · 7:41 AM UTC

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Read more